<DOC>
	<DOCNO>NCT03016000</DOCNO>
	<brief_summary>This randomize , multi-center , phase III study evaluate ability thalidomide maintenance therapy prolong relapse-free survival diffuse large B cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Thalidomide Maintenance Treatment DLBCL</brief_title>
	<detailed_description>This randomize , phase III study evaluate ability thalidomide maintenance therapy prolong relapse-free survival ( RFS ) , diffuse large B cell lymphoma ( DLBCL ) .Patients enrol successful standard induction therapy ( CR CRu follow standard R-CHOP-like therapy 8 infusion rituximab plus CHOP-like chemotherapy ( 4-8 cycle ) . Patients follow event occurs define protocol . To evaluate clinical efficacy thalidomide maintenance therapy compare observation patient DLBCL achieve complete remission appropriate first-line therapy , measure RFS , 226 patient DLCBL recruit .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>NCCNIPI &gt; 1 , Known IPI , cell origin DHL time diagnosis , Negative pregnancy test , Men must agree father child therapy , 6 8 cycle RCHOP/like , total 8 x Rituximab , CR , CRu Transformed lymphoma , Secondary malignancy , HIV positive , Evidence CNS involvement , Cardiac dysfunction ( systolic ejection fraction &lt; 50 % ) , Creatinine &gt; 2.0 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Maintenance</keyword>
</DOC>